X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DIVIS LABORATORIES ASTRAZENECA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 85.0 32.4 262.3% View Chart
P/BV x 18.7 7.3 256.7% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
ASTRAZENECA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2781,142 111.9%   
Low Rs883533 165.6%   
Sales per share (Unadj.) Rs228.4146.6 155.8%  
Earnings per share (Unadj.) Rs10.433.0 31.4%  
Cash flow per share (Unadj.) Rs16.338.4 42.3%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs98.8222.8 44.3%  
Shares outstanding (eoy) m25.00265.47 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.75.7 82.8%   
Avg P/E ratio x104.225.3 411.2%  
P/CF ratio (eoy) x66.421.8 304.7%  
Price / Book Value ratio x10.93.8 291.0%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m27,008222,318 12.1%   
No. of employees `0001.410.8 12.6%   
Total wages/salary Rs m1,5354,561 33.7%   
Avg. sales/employee Rs Th4,210.93,616.0 116.5%   
Avg. wages/employee Rs Th1,132.2423.8 267.2%   
Avg. net profit/employee Rs Th191.1814.9 23.4%   
INCOME DATA
Net Sales Rs m5,71038,915 14.7%  
Other income Rs m1231,134 10.8%   
Total revenues Rs m5,83340,049 14.6%   
Gross profit Rs m46312,617 3.7%  
Depreciation Rs m1471,425 10.3%   
Interest Rs m013 0.0%   
Profit before tax Rs m43812,313 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1793,543 5.0%   
Profit after tax Rs m2598,770 3.0%  
Gross profit margin %8.132.4 25.0%  
Effective tax rate %40.828.8 141.9%   
Net profit margin %4.522.5 20.1%  
BALANCE SHEET DATA
Current assets Rs m3,20945,351 7.1%   
Current liabilities Rs m2,0706,507 31.8%   
Net working cap to sales %20.099.8 20.0%  
Current ratio x1.67.0 22.3%  
Inventory Days Days72127 57.1%  
Debtors Days Days3595 36.7%  
Net fixed assets Rs m79021,160 3.7%   
Share capital Rs m50531 9.4%   
"Free" reserves Rs m2,41958,625 4.1%   
Net worth Rs m2,46959,156 4.2%   
Long term debt Rs m00-   
Total assets Rs m4,60567,832 6.8%  
Interest coverage xNM926.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 216.1%   
Return on assets %5.612.9 43.4%  
Return on equity %10.514.8 70.8%  
Return on capital %17.720.8 85.1%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m30032,359 0.9%   
Fx outflow Rs m2,0159,042 22.3%   
Net fx Rs m-1,71523,317 -7.4%   
CASH FLOW
From Operations Rs m887,759 1.1%  
From Investments Rs m-94-4,783 2.0%  
From Financial Activity Rs mNA-3,142 0.0%  
Net Cashflow Rs m-6-166 3.4%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 15.7 19.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   12,856 31,796 40.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  BIOCON   UNICHEM LAB  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 305 Points Lower; FMCG and Finance Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 22, 2019 03:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - WOCKHARDT COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS